IMRX SEC Filings: 8-K, 10-Q, S-3 & 424B – Immuneering

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 15, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 12, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 13, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWImmuneering Corporation Appoints Grant C. Bogle to Board of Directors

Nov 9, 2026

8-K

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

Oct 29, 2026

8-K

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 5, 2026

8-K

Immuneering Corporation Appoints Andrew Gengos as Chief Financial Officer

Jun 15, 2026

8-K

Immuneering Corporation Announces Results of 2026 Annual Meeting of Stockholders

Jun 11, 2026

8-K

Immuneering Corporation Announces Positive Phase 2a Data for Atebimetinib in First-Line Pancreatic Cancer

Jun 1, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

REGISTERED OFFERING

Sep 25, 2025

424B5

PENDING FIXED PRICE OFFERING

Sep 24, 2025

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 9,177,209 | Warrants amount: 3,925,860 |

Sep 8, 2025

424B5

June 2025 ATM | Amount sold to date: $18,706,156 | Float: 30,016,759

Jun 23, 2025

424B5

ATM | Offering amount: $21,503,435 | Amount sold to date: $18,700,000 | Float: 30,004,794

Mar 20, 2025

424B5

SHELF OFFERING | Shares amount: 2,727,273 | Share price: $11.00 | Offering amount: $30,000,003.00

Apr 19, 2023

Registrations

TYPE

HEADLINE

FILED AT

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Sep 25, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Sep 24, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Sep 9, 2025

S-3

September 2025 SHELF | Shares amount: 9,177,209 | Warrants amount: 3,925,860

Sep 2, 2025

S-3

August 2025 SHELF

Aug 13, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 5, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 20, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 20, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 21, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 23, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 23, 2024

Ownerships

TYPE

HEADLINE

FILED AT

NEWBogle Grant C. (Reporting)

Nov 9, 2026

NEWBogle Grant C. (Reporting)

Nov 9, 2026

SCHEDULE 13G

BlackRock, Inc. (Filed by)

Jul 28, 2026

Gengos Andrew (Reporting)

Jul 17, 2026

Gengos Andrew (Reporting)

Jul 16, 2026

Zeskind Benjamin J. (Reporting)

Jun 24, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 9, 2025

CORRESP

Form CORRESP - Correspondence

Sep 4, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 4, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 21, 2025

CORRESP

Form CORRESP - Correspondence

Aug 18, 2025

LETTER

Form UPLOAD - SEC-generated letter

Aug 18, 2025

Immuneering Corporation IMRX · SEC Filings